Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS Rating: 5.03, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.03 new
Vol. 4, Issue 10 (2015)

Clinical-laboratory peculiarities of the course of infiltrative tuberculosis combined with chronic bronchitis in complex treatment using glucosaminyl muramyl pentapeptide

Author(s):
Melnyk OP, Ostrovskyi MM
Abstract:
Tuberculosis – is an infectious disease that affects not only antisocial population, but can affect any person. Whereas, it is transmitted by airborne droplets through coughing, sneezing or communication with the patient with active TB of the lungs, people with impaired immunity arising after such diseases as pneumonia, bronchitis, peptic ulcer, diabetes mellitus, can fall ill. According to WHO data this diagnosis is made approximately to 1.000 people in Europe, and the morbidity indexes show that it will be difficult to overcome TB on this continent during the coming 85 years. We have examined 40 patients with infiltrative tuberculosis combined with chronic bronchitis, of which 22 patients have taken immunomodulator together with anti-mycobacterial medicines, and 18 patients – only standard treatment scheme. The results of the study show the expediency of administration of the immunomodulator together with anti-TB medicines.
Pages: 101-102  |  865 Views  9 Downloads
How to cite this article:
Melnyk OP, Ostrovskyi MM. Clinical-laboratory peculiarities of the course of infiltrative tuberculosis combined with chronic bronchitis in complex treatment using glucosaminyl muramyl pentapeptide. Pharma Innovation 2015;4(10):101-102.
The Pharma Innovation Journal